244 related articles for article (PubMed ID: 12713619)
1. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.
Yamamoto H; Oda Y; Saito T; Sakamoto A; Miyajima K; Tamiya S; Tsuneyoshi M
Histopathology; 2003 May; 42(5):431-9. PubMed ID: 12713619
[TBL] [Abstract][Full Text] [Related]
2. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
3. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
5. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
7. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
9. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis for p53 and mdm2 in intracranial germ cell tumors.
Iwato M; Tachibana O; Tohma Y; Nitta H; Hayashi Y; Yamashita J
Acta Neuropathol; 2000 Jan; 99(1):21-5. PubMed ID: 10651023
[TBL] [Abstract][Full Text] [Related]
12. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
14. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
15. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
[TBL] [Abstract][Full Text] [Related]
16. Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.
Hou TC; Wu PS; Huang WY; Yang YT; Tan KT; Liu SH; Chen YJ; Chen SJ; Su YW
Medicine (Baltimore); 2020 Mar; 99(12):e19577. PubMed ID: 32195970
[TBL] [Abstract][Full Text] [Related]
17. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.
Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H
Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942
[TBL] [Abstract][Full Text] [Related]
18. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
19. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
20. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
